Liquid biopsy test detected patients at risk for CRC relapse

A liquid biopsy test that detects circulating tumor DNA identified patients likely to redevelop colorectal cancer after having undergone surgery to remove tumors, Medpage Today reported Jan. 17.

Researchers had 218 patients take the ctDNA test: 20 had detectable ctDNA and 15 of those patients had CRC recurrence. Five patients who didn't have disease recurrence all received adjuvant chemotherapy. Researchers believe targeting patients likely to redevelop CRC with chemotherapy could prevent the relapse.

Among 198 patients who tested negative for ctDNA, 13.5 percent redeveloped the disease.

Researchers presented results from the study at the Gastrointestinal Cancers Symposium virtual meeting, Jan.15-17.

Tenna V. Henriksen, a PhD candidate at Aarhus University in Denmark, said to Medpage Today: "We saw that patients with ctDNA detected immediately after surgery had a very high risk of recurrence. We also saw that longitudinal monitoring increased the predictive power of ctDNA."

Read the entire article here.

More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don't
Stryker's ASC-focused business: 3 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers